rs775170915
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_014625.4(NPHS2):βc.948delβ(p.Ala317LeufsTer31) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000415 in 1,613,950 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ).
Frequency
Genomes: π 0.000013 ( 0 hom., cov: 32)
Exomes π: 0.000044 ( 0 hom. )
Consequence
NPHS2
NM_014625.4 frameshift
NM_014625.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -1.17
Genes affected
NPHS2 (HGNC:13394): (NPHS2 stomatin family member, podocin) This gene encodes a protein that plays a role in the regulation of glomerular permeability. Mutations in this gene cause steroid-resistant nephrotic syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. There are 14 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 1-179551376-CA-C is Pathogenic according to our data. Variant chr1-179551376-CA-C is described in ClinVar as [Pathogenic]. Clinvar id is 188990.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-179551376-CA-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NPHS2 | NM_014625.4 | c.948del | p.Ala317LeufsTer31 | frameshift_variant | 8/8 | ENST00000367615.9 | NP_055440.1 | |
AXDND1 | NM_144696.6 | c.3032-3135del | intron_variant | ENST00000367618.8 | NP_653297.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NPHS2 | ENST00000367615.9 | c.948del | p.Ala317LeufsTer31 | frameshift_variant | 8/8 | 1 | NM_014625.4 | ENSP00000356587 | P1 | |
AXDND1 | ENST00000367618.8 | c.3032-3135del | intron_variant | 1 | NM_144696.6 | ENSP00000356590 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152140Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
152140
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 251028Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135632
GnomAD3 exomes
AF:
AC:
3
AN:
251028
Hom.:
AF XY:
AC XY:
1
AN XY:
135632
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000445 AC: 65AN: 1461810Hom.: 0 Cov.: 34 AF XY: 0.0000399 AC XY: 29AN XY: 727202
GnomAD4 exome
AF:
AC:
65
AN:
1461810
Hom.:
Cov.:
34
AF XY:
AC XY:
29
AN XY:
727202
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152140Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74322
GnomAD4 genome
AF:
AC:
2
AN:
152140
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74322
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Nephrotic syndrome, type 2 Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 17, 2020 | Variant summary: NPHS2 c.948delT (p.Ala317LeufsX31) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 1.2e-05 in 251028 control chromosomes. c.948delT has been reported in the literature in multiple individuals affected with Nephrotic Syndrome, Type 2, also known as Steroid-resistant nephrotic syndrome type 2 (example, Ruf_2004, Billing_2004, Hinkes_2008, Lwik_2008). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Mar 02, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 22, 2024 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 19, 2018 | The c.948delT variant in the NPHS2 gene has been reported previously in the compound heterozygous state with a second NPHS2 variant in individuals with steroid-resistant nephrotic syndrome (Lowik et al., 2008; Kerti et al., 2013). The c.948delT variant causes a frameshift starting with codon Alanine 317, changes this amino acid to a Leucine residue, and creates a premature Stop codon at position 31 of the new reading frame, denoted p.Ala317LeufsX31. This variant is predicted to cause loss of normal protein function through protein truncation, as the last 67 amino acids are lost and replaced with 30 incorrect amino acids. The c.948delT variant is observed in 1/24,024 (0.004%) alleles from individuals of African background and 4/276,734 (0.001%) total alleles in large population cohorts (Lek et al., 2016). We interpret c.948delT as a pathogenic variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Nov 01, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 27, 2023 | This sequence change creates a premature translational stop signal (p.Ala317Leufs*31) in the NPHS2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 67 amino acid(s) of the NPHS2 protein. This variant is present in population databases (rs775170915, gnomAD 0.004%). This premature translational stop signal has been observed in individuals with steroid-resistant nephrotic syndrome (PMID: 14978175, 18443213, 23242530). This variant is also known as p.L347X. ClinVar contains an entry for this variant (Variation ID: 188990). For these reasons, this variant has been classified as Pathogenic. - |
Steroid-resistant nephrotic syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Nov 06, 2020 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at